Varun Sagi, Waogwende L. Song-Naba, Barbara A. Benson, Sonal S. Joshi, Kalpna Gupta
下载PDF
{"title":"Mouse Models of Pain in Sickle Cell Disease","authors":"Varun Sagi, Waogwende L. Song-Naba, Barbara A. Benson, Sonal S. Joshi, Kalpna Gupta","doi":"10.1002/cpns.54","DOIUrl":null,"url":null,"abstract":"<p>Sickle cell disease (SCD) is a genetic blood disorder that impacts millions of individuals worldwide. SCD is characterized by debilitating pain that can begin during infancy and may continue to increase throughout life. This pain can be both acute and chronic. A characteristic feature specific to acute pain in SCD occurs during vaso-occlusive crisis (VOC) due to the blockade of capillaries with sickle red blood cells. The acute pain of VOC is intense, unpredictable, and requires hospitalization. Chronic pain occurs in a significant population with SCD. Treatment options for sickle pain are limited and primarily involve the use of opioids. However, long-term opioid use is associated with numerous side effects. Thus, pain management in SCD remains a major challenge. Humanized transgenic mice expressing exclusively human sickle hemoglobin show features of pain and pathobiology similar to that in patients with SCD. Therefore, these mice offer the potential for investigating the mechanisms of pain in SCD and allow for development of novel targeted analgesic therapies. © 2018 by John Wiley & Sons, Inc.</p>","PeriodicalId":40016,"journal":{"name":"Current Protocols in Neuroscience","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/cpns.54","citationCount":"14","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Protocols in Neuroscience","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cpns.54","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Neuroscience","Score":null,"Total":0}
引用次数: 14
引用
批量引用
Abstract
Sickle cell disease (SCD) is a genetic blood disorder that impacts millions of individuals worldwide. SCD is characterized by debilitating pain that can begin during infancy and may continue to increase throughout life. This pain can be both acute and chronic. A characteristic feature specific to acute pain in SCD occurs during vaso-occlusive crisis (VOC) due to the blockade of capillaries with sickle red blood cells. The acute pain of VOC is intense, unpredictable, and requires hospitalization. Chronic pain occurs in a significant population with SCD. Treatment options for sickle pain are limited and primarily involve the use of opioids. However, long-term opioid use is associated with numerous side effects. Thus, pain management in SCD remains a major challenge. Humanized transgenic mice expressing exclusively human sickle hemoglobin show features of pain and pathobiology similar to that in patients with SCD. Therefore, these mice offer the potential for investigating the mechanisms of pain in SCD and allow for development of novel targeted analgesic therapies. © 2018 by John Wiley & Sons, Inc.
镰状细胞病小鼠疼痛模型
镰状细胞病(SCD)是一种影响全球数百万人的遗传性血液疾病。SCD的特点是虚弱的疼痛,可以在婴儿期开始,并可能在整个生命中持续增加。这种疼痛可以是急性的,也可以是慢性的。SCD急性疼痛的一个特征性特征发生在血管闭塞危象(VOC)期间,由于镰状红细胞阻塞毛细血管。VOC的急性疼痛是强烈的,不可预测的,需要住院治疗。慢性疼痛发生在SCD的重要人群中。镰状痛的治疗选择有限,主要涉及阿片类药物的使用。然而,长期使用阿片类药物会产生许多副作用。因此,SCD的疼痛管理仍然是一个主要的挑战。仅表达人镰状血红蛋白的人源化转基因小鼠表现出与SCD患者相似的疼痛和病理生物学特征。因此,这些小鼠提供了研究SCD疼痛机制的潜力,并允许开发新的靶向镇痛疗法。©2018 by John Wiley &儿子,Inc。
本文章由计算机程序翻译,如有差异,请以英文原文为准。